Company: RGNT
Filing Date: 2025-07-07
Form Type: F-1/A
Source: 0001213900-25-061821
Chunk: 253

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-07-07
Form: F-1/A
Chunk 253
---
. | Cash and cash equivalents: |

Cash equivalents are short-term highly
liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition.

| e. | Fair Value Measurements: |

The carrying values of Company’s
financial assets and liabilities, including cash and cash equivalents, other current assets, trade payables, other accounts payable and
short-term loan, approximate their fair value due to the short-term maturity of these instruments. Fair value is defined as the price
that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants
at the reporting date. Assets and liabilities recorded at fair value in the financial statements are categorized based upon the level
of judgment associated with the inputs used to measure their fair value. Hierarchical levels are directly related to the amount of subjectivity
with the inputs to the valuation of these assets or liabilities as follows:

| Level 1 | – | Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities 
 at the measurement date;                                                                                  |

| Level 2 | – | Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable                                     
 inputs for similar assets or liabilities. These include quoted prices for identical or similar assets or liabilities in active markets 
 and quoted prices for identical or similar assets of liabilities in markets that are not active;                                       |

| Level 3 | – | Unobservable inputs that are supported by little or no market activity and that are significant to 
 the fair value of the assets or liabilities.                                                       |

The convertible notes and warrant liability
are classified within Level 3 of the fair value hierarchy because their fair values are estimated by utilizing valuation models and significant
unobservable inputs.

| f. | Research and development expenses: |

Research and development expenses are
charged to the statements of comprehensive loss as incurred.

<div align='center'>F-9</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 2:- | SIGNIFICANT ACCOUNTING POLICIES (Cont.) |

| g. | Income taxes: |

The Company accounts for income taxes
in accordance with ASC 740, Income Taxes(“ASC 740”). ASC 740 prescribes the use of the liability method whereby deferred
tax assets and liability account balances are determined based on differences between financial reporting and tax bases of